Please assess the completion status of the following clinical trial:

Trial Title: PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with lymphoid malignancies: CR1 or CR2 for acute lymphoblastic leukemia; T cell lymphoma (any CR/PR); B cell lymphoma (PR1 or CR2), hodgkin's disease (CR2 or beyond), Sezary syndrome~* patients with HLA matched sibling, unrelated (HLA 9\~10/10 matched) or haplo-identical donor~Exclusion Criteria:~* patients with active infection~* patients with abnormal liver function damage: ALT/AST above 2X normal range~* patients with abnormal renal function damage Scr\>160µmol/L;~* patients with insufficient pulmonary function (FEV1，FVC，DLCO\<50%）and heart failure or with EF \<50%)~* patients with mental instability~* unwilling to give inform consent

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- PT-CY-FK +/- ATG (Type: EXPERIMENTAL): GVHD prophylaxis: PT-CY followed by tacrolimus for all patients. low-dose ATG for patients with unrelated or haplo-identical transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).